Education
About Us
Working with TipRanks
Follow Us
Zentalis Pharmaceuticals (ZNTL)
NASDAQ:ZNTL
RESEARCH TOOLSreports
ZNTL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.61 - $16.27
Previous CloseN/A
Volume750.15K
Average Volume (3M)2.30M
Market Cap
$133.27M
Enterprise Value-$86.30M
Total Cash (Recent Filing)$37.62M
Total Debt (Recent Filing)$45.35M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
May 07, 2025EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.53
Shares Outstanding71,265,400
10 Day Avg. Volume1,052,857
30 Day Avg. Volume2,303,368
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.37
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit62.13
Enterprise Value/Ebitda0.41
Forecast
1Y Price Target
$5.97Price Target Upside219.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
---
Zentalis Pharmaceuticals News
PremiumCompany Announcements
Zentalis Pharmaceuticals Announces New Study for Azenosertib
---
Bulls Say, Bears Say
Bulls Say
Efficacy And SafetyZNTL's safety profile for its treatment appears generally superior to standard chemotherapy, which is a reassuring factor for investors.
Regulatory PathwayWith a clear regulatory pathway, a biomarker-driven strategy, and a significant market opportunity, Zentalis is well-positioned to deliver a transformative therapy for PROC patients.
Bears Say
FDA RequirementsThe FDA is requesting further dose optimization for the 400mg regimen, indicating that the current dose may not be optimal yet.
Price Target AdjustmentsThe company's price target has been reduced from $7.00 to $5.00, reflecting adjustments in the company's latest pipeline and strategy.
---
Ownership Overview
5.16% Insiders
28.15% Mutual Funds
45.97% Other Institutional Investors
12.05% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ZNTL FAQ
What was Zentalis Pharmaceuticals’s price range in the past 12 months?
Zentalis Pharmaceuticals lowest stock price was $1.61 and its highest was $16.27 in the past 12 months.
What is Zentalis Pharmaceuticals’s market cap?
Zentalis Pharmaceuticals’s market cap is $133.27M.
When is Zentalis Pharmaceuticals’s upcoming earnings report date?
Zentalis Pharmaceuticals’s upcoming earnings report date is May 07, 2025 which is in 62 days.
How were Zentalis Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Zentalis Pharmaceuticals overvalued?
According to Wall Street analysts Zentalis Pharmaceuticals’s price is currently Undervalued.
Does Zentalis Pharmaceuticals pay dividends?
Zentalis Pharmaceuticals does not currently pay dividends.
What is Zentalis Pharmaceuticals’s EPS estimate?
Zentalis Pharmaceuticals’s EPS estimate is -0.69.
How many shares outstanding does Zentalis Pharmaceuticals have?
Zentalis Pharmaceuticals has 71,265,400 shares outstanding.
What happened to Zentalis Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Zentalis Pharmaceuticals?
Currently, no hedge funds are holding shares in ZNTL
---
Zentalis Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.97 (219.25% Upside)
$5.97 (219.25% Upside)
Blogger Sentiment
Bullish
ZNTL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 486.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $157.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 9.4%
Last 30 Days ▲ 9.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-87.12%
12-Months-Change
Fundamentals
Return on Equity
-42.89%
Trailing 12-Months
Asset Growth
-23.06%
Trailing 12-Months
Company Description
Zentalis Pharmaceuticals
Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. The company's product candidate, ZN-c5, is an oral selective estrogen receptor degrader, or SERD, currently in a Phase 1/2 clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer. Its other products include ZN-c3, ZN-d5, and ZN-e4.
---
ZNTL Stock 12 Month Forecast
Average Price Target
$5.97
▲(219.25% Upside)
Technical Analysis
Best Analysts Covering ZNTL
1 Year
1 Year Success Rate
1/15 ratings generated profit
1 Year Average Return
-49.57%
reiterated a buy rating last month
Copying Matthew Biegler's trades and holding each position for 1 Year would result in 6.67% of your transactions generating a profit, with an average return of -49.57% per trade.
---